| Nov 21 |
Apellis started at equal-weight at Morgan Stanley on geographic atrophy market
|
| Nov 12 |
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
|
| Nov 7 |
Apellis price target lowered to $30 from $43 at Wells Fargo
|
| Nov 7 |
Apellis price target lowered to $47 from $61 at BofA
|
| Nov 6 |
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
|
| Nov 6 |
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ...
|
| Nov 5 |
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
|
| Nov 5 |
Apellis Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 5 |
Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript
|
| Nov 5 |
Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say
|
